Youtube
Twitter
Facebook
RepliCel’s Chief Scientific Officer Updates World Congress for Hair Research on 12-Month Safety Data from its Phase I Clinical Trial
VANCOUVER, BC – May 3, 2013 – RepliCel Life Sciences Inc.(the “Company” or “RepliCel”) (OTCBB: REPCF) (CDNX: RP) reports that its Chief Scientific Officer, Dr. Kevin McElwee, will be presenting at the 7th World Congress for Hair Research in Edinburg, Scotland from May 4-6th , 2013. Dr. McElwee will be discussing 12-month safety results from ... Continue reading
RepliCel to Present at the 11th Annual BioPartnering North America Conference
Vancouver Convention Centre, Vancouver, BC, February 24-26th, 2013 VANCOUVER, BC – February 19th 2013 – RepliCel Life Sciences Inc (the “Company” or “RepliCel”) (OTCBB: REPCF) (CNSX: RP) today announced that the Company will present to a select group of biotech industry investors and experts at the 11th Annual BioPartnering North America Conference (“BPN”) in Vancouver, ... Continue reading
RepliCel to Meet with German Competent Authority on its RCH-01 Autologous Hair Cell Manufacturing Process
Phase II Dose Ranging Trial Planned for 2013 VANCOUVER, BC – February 4, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCBB: REPCF) is pleased to report that it will be meeting with the German Competent Authority responsible for cellular therapies (the Paul Ehrlich Institute (PEI)) to discuss plans for its upcoming Phase ... Continue reading
Notice of Annual Meeting of Shareholders to be held June 11, 2012
RepliCel Life Sciences Inc. will be hosting its Annual Meeting of Shareholders on Monday, June 11, 2012 at the Metropolitan Hotel in Vancouver, B.C. at 10:00 A.M. local time. Location: Metropolitan Hotel Vancouver 645 Howe Street Vancouver, BC V6C 2Y9 Please click here for a map: http://maps.google.ca/maps?q=645+Howe+StreetVancouver,+BC+V6C+2Y9&ll=49.283904,-123.118147&spn=0.005634,0.016512&oe=utf-8&client=firefox-a&t=m&z=17&vpsrc=6 Information Circular and Proxy materials will be sent ... Continue reading
David Hall Discusses Six Month Results from Phase I/IIa Clinical Trial
Viral Networks Inc. recently interviewed David Hall, President and CEO of RepliCel. In the interview, he discusses the interim results from RepliCel’s first-in-man clinical trial. For the full video, please visit http://www.youtube.com/watch?v=9SjQAfiKAk0. ... Continue reading